Abstract 14423: A Retrospective Analysis of a Single-Center Experience With the Tempo Temporary Pacing Lead in Management of Bradyarrhythmia and Other Cardiac Electrophysiology Procedures

Abstract

Introduction: Acute temporary pacing lead dislodgment may result in cardiac perforation, loss of pacing capture and proarrhythmia by means of under-sensing or mechanical stimulation. We report the results of a single-center retrospective study of the safety and efficacy of the Tempo® Temporary Pacing Lead (BioTrace Medical, Menlo Park, CA), which has a novel active fixation mechanism designed to enhance pacing stability and a soft tip to mitigate perforation. Methods: Twelve consecutive patients (83% male, mean age 71.3 ± 10.1 years) who underwent Tempo Lead placement for temporary pacing (75% symptomatic bradyarrhythmia, 25% other indication) were retrospectively reviewed. Safety (including perforation, new pericardial effusion, and sustained device-related arrhythmias) and efficacy (clinically acceptable pacing thresholds with stable pace capture over the temporary implant duration) data were assessed. The study also evaluated post-procedural practices such as ambulation. Results: The Tempo Lead was successfully positioned and fixed in the right ventricle in all 12 cases with no perforations, pericardial effusions, or device-related arrhythmias. Access was femoral in 8 patients (67%) and jugular in 3 patients (25%), with one access point not indicated. Procedural mean pace capture threshold (PCT) was 0.96 ± 0.74 mA (n=10). Mean lead indwelling duration was 53.5 hours with a range of 20.9 hours to 5.9 days (n= 11). Three patients were ambulatory (at least bed-to-chair) with the Tempo Lead in place without complications and with maintenance of thresholds <1mA. Conclusions: This single-center retrospective analysis demonstrates that the Tempo Lead is safe and effective for temporary pacing and early ambulation in cardiac electrophysiology procedures.